Table of Contents Chapter 1 Overview of Becker Muscular Dystrophy Drug 1.1 Definition of Becker Muscular Dystrophy Drug in This Report 1.2 Commercial Types of Becker Muscular Dystrophy Drug 1.2.1 Givinostat 1.2.2 Ataluren 1.2.3 Epicatechin 1.2.4 ARM-210 1.2.5 Others 1.3 Downstream Application of Becker Muscular Dystrophy Drug 1.3.1 Hospital 1.3.2 Clinic 1.3.3 Others 1.4 Development History of Becker Muscular Dystrophy Drug 1.5 Market Status and Trend of Becker Muscular Dystrophy Drug 2013-2023 1.5.1 Europe Becker Muscular Dystrophy Drug Market Status and Trend 2013-2023 1.5.2 Regional Becker Muscular Dystrophy Drug Market Status and Trend 2013-2023 Chapter 2 Europe Market Status and Forecast by Regions 2.1 Market Status of Becker Muscular Dystrophy Drug in Europe 2013-2017 2.2 Consumption Market of Becker Muscular Dystrophy Drug in Europe by Regions 2.2.1 Consumption Volume of Becker Muscular Dystrophy Drug in Europe by Regions 2.2.2 Revenue of Becker Muscular Dystrophy Drug in Europe by Regions 2.3 Market Analysis of Becker Muscular Dystrophy Drug in Europe by Regions 2.3.1 Market Analysis of Becker Muscular Dystrophy Drug in Germany 2013-2017 2.3.2 Market Analysis of Becker Muscular Dystrophy Drug in United Kingdom 2013-2017 2.3.3 Market Analysis of Becker Muscular Dystrophy Drug in France 2013-2017 2.3.4 Market Analysis of Becker Muscular Dystrophy Drug in Italy 2013-2017 2.3.5 Market Analysis of Becker Muscular Dystrophy Drug in Spain 2013-2017 2.3.6 Market Analysis of Becker Muscular Dystrophy Drug in Benelux 2013-2017 2.3.7 Market Analysis of Becker Muscular Dystrophy Drug in Russia 2013-2017 2.4 Market Development Forecast of Becker Muscular Dystrophy Drug in Europe 2018-2023 2.4.1 Market Development Forecast of Becker Muscular Dystrophy Drug in Europe 2018-2023 2.4.2 Market Development Forecast of Becker Muscular Dystrophy Drug by Regions 2018-2023 Chapter 3 Europe Market Status and Forecast by Types 3.1 Whole Europe Market Status by Types 3.1.1 Consumption Volume of Becker Muscular Dystrophy Drug in Europe by Types 3.1.2 Revenue of Becker Muscular Dystrophy Drug in Europe by Types 3.2 Europe Market Status by Types in Major Countries 3.2.1 Market Status by Types in Germany 3.2.2 Market Status by Types in United Kingdom 3.2.3 Market Status by Types in France 3.2.4 Market Status by Types in Italy 3.2.5 Market Status by Types in Spain 3.2.6 Market Status by Types in Benelux 3.2.7 Market Status by Types in Russia 3.3 Market Forecast of Becker Muscular Dystrophy Drug in Europe by Types Chapter 4 Europe Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Becker Muscular Dystrophy Drug in Europe by Downstream Industry 4.2 Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Major Countries 4.2.1 Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Germany 4.2.2 Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in United Kingdom 4.2.3 Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in France 4.2.4 Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Italy 4.2.5 Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Spain 4.2.6 Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Benelux 4.2.7 Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Russia 4.3 Market Forecast of Becker Muscular Dystrophy Drug in Europe by Downstream Industry Chapter 5 Market Driving Factor Analysis of Becker Muscular Dystrophy Drug 5.1 Europe Economy Situation and Trend Overview 5.2 Becker Muscular Dystrophy Drug Downstream Industry Situation and Trend Overview Chapter 6 Becker Muscular Dystrophy Drug Market Competition Status by Major Players in Europe 6.1 Sales Volume of Becker Muscular Dystrophy Drug in Europe by Major Players 6.2 Revenue of Becker Muscular Dystrophy Drug in Europe by Major Players 6.3 Basic Information of Becker Muscular Dystrophy Drug by Major Players 6.3.1 Headquarters Location and Established Time of Becker Muscular Dystrophy Drug Major Players 6.3.2 Employees and Revenue Level of Becker Muscular Dystrophy Drug Major Players 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Becker Muscular Dystrophy Drug Major Manufacturers Introduction and Market Data 7.1 Italfarmaco SpA 7.1.1 Company profile 7.1.2 Representative Becker Muscular Dystrophy Drug Product 7.1.3 Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of Italfarmaco SpA 7.2 Milo Biotechnology LLC 7.2.1 Company profile 7.2.2 Representative Becker Muscular Dystrophy Drug Product 7.2.3 Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of Milo Biotechnology LLC 7.3 PTC Therapeutics Inc 7.3.1 Company profile 7.3.2 Representative Becker Muscular Dystrophy Drug Product 7.3.3 Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of PTC Therapeutics Inc 7.4 ReveraGen BioPharma Inc 7.4.1 Company profile 7.4.2 Representative Becker Muscular Dystrophy Drug Product 7.4.3 Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of ReveraGen BioPharma Inc 7.5 Sarepta Therapeutics Inc 7.5.1 Company profile 7.5.2 Representative Becker Muscular Dystrophy Drug Product 7.5.3 Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of Sarepta Therapeutics Inc Chapter 8 Upstream and Downstream Market Analysis of Becker Muscular Dystrophy Drug 8.1 Industry Chain of Becker Muscular Dystrophy Drug 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Becker Muscular Dystrophy Drug 9.1 Cost Structure Analysis of Becker Muscular Dystrophy Drug 9.2 Raw Materials Cost Analysis of Becker Muscular Dystrophy Drug 9.3 Labor Cost Analysis of Becker Muscular Dystrophy Drug 9.4 Manufacturing Expenses Analysis of Becker Muscular Dystrophy Drug Chapter 10 Marketing Status Analysis of Becker Muscular Dystrophy Drug 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Givinostat Table Advantage and Disadvantage of Ataluren Table Advantage and Disadvantage of Epicatechin Table Advantage and Disadvantage of ARM-210 Table Advantage and Disadvantage of Others Table Consumption Volume of Becker Muscular Dystrophy Drug in Europe by Regions 2013-2017 Table Revenue of Becker Muscular Dystrophy Drug in Europe by Regions 2013-2017 Table Consumption Volume of Becker Muscular Dystrophy Drug in Europe by Regions 2018-2023 Table Revenue of Becker Muscular Dystrophy Drug in Europe by Regions 2018-2023 Table Consumption Volume of Becker Muscular Dystrophy Drug in Europe by Types 2013-2017 Table Revenue of Becker Muscular Dystrophy Drug in Europe by Types 2013-2017 Table Consumption Volume of Becker Muscular Dystrophy Drug by Types in Germany 2013-2017 Table Consumption Volume of Becker Muscular Dystrophy Drug by Types in United Kingdom 2013-2017 Table Consumption Volume of Becker Muscular Dystrophy Drug by Types in France 2013-2017 Table Consumption Volume of Becker Muscular Dystrophy Drug by Types in Italy 2013-2017 Table Consumption Volume of Becker Muscular Dystrophy Drug by Types in Spain 2013-2017 Table Consumption Volume of Becker Muscular Dystrophy Drug by Types in Benelux 2013-2017 Table Consumption Volume of Becker Muscular Dystrophy Drug by Types in Russia 2013-2017 Table Consumption Volume Forecast of Becker Muscular Dystrophy Drug in Europe by Types 2018-2023 Table Revenue Forecast of Becker Muscular Dystrophy Drug in Europe by Types 2018-2023 Table Demand Volume of Becker Muscular Dystrophy Drug in Europe by Downstream Industry 2013-2017 Table Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Germany 2013-2017 Table Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in United Kingdom 2013-2017 Table Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in France 2013-2017 Table Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Italy 2013-2017 Table Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Spain 2013-2017 Table Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Benelux 2013-2017 Table Demand Volume of Becker Muscular Dystrophy Drug by Downstream Industry in Russia 2013-2017 Table Demand Volume Forecast of Becker Muscular Dystrophy Drug in Europe by Downstream Industry 2018-2023 Table Sales Volume of Becker Muscular Dystrophy Drug in Europe by Major Players 2013-2017 Table Revenue of Becker Muscular Dystrophy Drug in Europe by Major Players 2013-2017 Table Headquarters Location and Established Time of Becker Muscular Dystrophy Drug Major Players Table Employees and Revenue Level of Becker Muscular Dystrophy Drug Major Players Table Representative Becker Muscular Dystrophy Drug Product One of Italfarmaco SpA Table Representative Becker Muscular Dystrophy Drug Product Two of Italfarmaco SpA Table Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of Italfarmaco SpA 2013-2017 Table Representative Becker Muscular Dystrophy Drug Product One of Milo Biotechnology LLC Table Representative Becker Muscular Dystrophy Drug Product Two of Milo Biotechnology LLC Table Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of Milo Biotechnology LLC 2013-2017 Table Representative Becker Muscular Dystrophy Drug Product One of PTC Therapeutics Inc Table Representative Becker Muscular Dystrophy Drug Product Two of PTC Therapeutics Inc Table Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of PTC Therapeutics Inc 2013-2017 Table Representative Becker Muscular Dystrophy Drug Product One of ReveraGen BioPharma Inc Table Representative Becker Muscular Dystrophy Drug Product Two of ReveraGen BioPharma Inc Table Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of ReveraGen BioPharma Inc 2013-2017 Table Representative Becker Muscular Dystrophy Drug Product One of Sarepta Therapeutics Inc Table Representative Becker Muscular Dystrophy Drug Product Two of Sarepta Therapeutics Inc Table Becker Muscular Dystrophy Drug Sales, Revenue, Price and Gross Margin of Sarepta Therapeutics Inc 2013-2017